Showing 3781-3790 of 4678 results for "".
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology</
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and
- Data: Acne Sufferers Lack Understanding About Use of Antibiotics to Treat Acne and Potential Resistancehttps://practicaldermatology.com/news/data-acne-sufferers-lack-understanding-about-use-of-antibiotics-to-treat-acne-and-potential-resistance/2458797/A recent survey sponsored by Galderma Laboratories, L.P., inclusive of 809 acne sufferers (ages 17-40 years) and 210 parents of acne sufferers (child, aged 9-17 years), found that despite the risk of antibiotic resistance and potential side effects:
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op
- Dermatologist Harold Lancer and Ryan Seacrest Collaborate on Male Skincare Linehttps://practicaldermatology.com/news/dermatologist-harold-lancer-and-ryan-seacrest-collaborate-on-male-skincare-line/2458814/Dr. Harold Lancer and radio personality, television host and producer Ryan Seacrest have revealed an exclusive partnership in the burgeoning men's grooming category. They plan to launch a men's skincare line late in 2016. This pairing combines Dr. Lan
- Diplomat Pharmacy to Dispense Cotellic®https://practicaldermatology.com/news/diplomat-pharmacy-to-dispense-cotellic/2458816/Diplomat Pharmacy, Inc. will dispense Cotellic® (cobimetinib) in combination with the BRAF inhibitor Zelboraf® (vemurafenib) to treat patients with advanced melanoma that is unrespectable or metastatic. The com